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Abstract A fully functional cysteine-free derivative of the
intrinsically stable anti-HER2 scFv fragment hu4D5^8 was
generated by replacing the disulfide forming cysteine residues in
VH and VL with the amino acid combination valine-alanine in
both domains. The antigen binding properties, determined by
ELISA and BIAcore measurements, were not affected by
removal of the disulfide bonds. The thermodynamic stability of
the disulfide-containing scFv of 8.1 kcal/mol is decreased upon
complete reduction of both disulfides to 2.7 kcal/mol, while that
of the valine-alanine variant is somewhat higher (about 3.8 kcal/
mol). Our results suggest that, in principle, a disulfide-free fully
functional derivative of any scFv can be obtained, as long as the
corresponding disulfide-containing scFv has a high enough
thermodynamic stability.
z 1998 Federation of European Biochemical Societies.
Key words: Disul¢de bond; ScFv fragment; Intrabody;
Antibody engineering; Protein stability
1. Introduction
Antibody domains carry an internal disul¢de bond, which
connects both L-sheets of the L-sandwich structure and is
strictly conserved in evolution ([1^4]), witnessing its important
contribution to the stability of the folded domain. Goto and
Hamaguchi [5] have ¢rst experimentally demonstrated the
strongly stabilizing e¡ect by measuring the energy loss ob-
served when refolding reduced CL domains. Genetic removal
of the disul¢de bonds in the variable domains of the Fv, scFv
or Fab fragment of the antibody McPC603 yielded no func-
tional protein, suggesting a severe loss of stability in all var-
iants tested, as well as in the reduced wild-type protein [6].
However, there are several antibodies in the database,
which lack the conserved disul¢de bridge in one of the do-
mains. One of them, for which functionality has been proven,
is the levan binding antibody ABPC48 ([7,8]), which has cys-
teine H92 in the heavy chain changed to tyrosine by somatic
mutation. This antibody has been further studied in a scFv
format [3], and restoration of the VH disul¢de bond resulted
in a scFv fragment with above average stability [3]. The re-
maining disul¢de bridge in the light chain of the A48 scFv
could also be removed and a functional, completely cysteine-
free antibody was obtained. However, this was only possible
by introducing several additional mutations during an evolu-
tionary approach, in which DNA shu¥ing [9] and selection
for functionality by phage panning were alternated [10]. Some
of the additional mutations created during DNA shu¥ing
showed a globally stabilizing e¡ect (A. Woºrn et al., manu-
script submitted).
It was also possible to remove the disul¢de bond from the
VL domain REIv-U, after introducing a globally stabilizing
mutation ([11,12]). The structure of the disul¢de-free REIv-U
VL domain has been solved and was found to be essentially
identical with the disul¢de-containing REIv-U domain [13].
Taken together, these results suggest that the disul¢de bonds
can be removed only from very stable antibody variable do-
mains.
There is great interest in obtaining disul¢de-free functional
antibodies, because they could be expressed as intracellular
antibodies (intrabodies) in the reducing environment of the
cytoplasm ([14^16]). Many interesting applications can be en-
visaged, where antibodies would have to ‘titrate out’ cellular
proteins. Intrabody studies carried out until now have been
performed with antibodies still carrying the conserved cys-
teines. Because of the strongly reducing environment of the
cytoplasm [17] it must be assumed that the disul¢des do not
form under these conditions. Indeed, this has been shown for
one scFv fragment [18]. Nevertheless, the antibodies seemed
to bind their antigen intracellularly, at least in the published
experiments (for representative examples, see [19^21]). How-
ever, it cannot be excluded that only a small fraction of these
intrabodies will be folded correctly. Thus, even better results
may be achievable and a wider variety of antibodies may be
functional when using antibodies optimized to fold in a disul-
¢de-free format. In the case of the disul¢de-free A48 scFv it
could be shown by ELISA of crude cell extracts that the
stabilized disul¢de-free derivative was indeed more functional
under reducing cytoplasmic conditions than a control A48wt
scFv still carrying the cysteines in the heavy chain [10].
In the present study we wanted to test the generality of the
concept that global stabilization is the prerequisite for disul-
¢de removal. The successful production of the disul¢de-free
A48 scFv is so far the only one that has been reported. How-
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ever, the A48 may be an unusual antibody, since it appears
that the unpaired Cys H22 can face outward [3]. We thus
wanted to test whether the ability to obtain the mutated
A48 scFv fragment in a completely disul¢de-free, correctly
folded form had to do with this structural peculiarity. To
address this question we investigated whether another ‘nor-
mal’ but very stable scFv can be converted to a stable disul-
¢de-free form.
We have chosen the hu4D5^8 framework [22] to create a
cysteine-free scFv for several reasons. First, the hu4D5 scFv,
which binds the extracellular domain of human epidermal
growth factor receptor-2 (p185HER2ÿECD) [23], has repeatedly
been used in successful CDR grafting experiments ([24,25]).
Therefore, a potential disul¢de-free hu4D5 framework should
also provide a promising framework for grafting di¡erent
speci¢cities, which could then be tested in intrabody studies.
Second, one of the grafts derived from the hu4D5^8 scFv was
shown to have above average thermodynamic stability [24], as
does the hu4D5^8 scFv itself (shown in this study). We there-
fore reasoned that, from an energetic point of view, it might
be possible to remove the conserved disul¢de bridges without
having to introduce any further stabilizing mutations in this
framework, and still obtain acceptable stability.
The resulting cysteine-free hu4D5^8 scFv fragment (termed
4D5-SS3) and a control hu4D5^8 scFv in exactly the same
format, but still carrying the disul¢de bridges (termed 4D5-
SS), were puri¢ed and analyzed to prove that the removal of
the disul¢de bonds has no in£uence on the functionality of the
scFv fragment. This was demonstrated qualitatively by ELI-
SA and quantitatively by BIAcore measurements [26]. In ad-
dition, the thermodynamic stabilities of the two scFv frag-
ments and the dithiol form of the cysteine-containing
variant were compared by urea induced equilibrium unfold-
ing.
2. Materials and methods
2.1. Construction of expression vectors
VH and VL domains were PCR ampli¢ed separately from a vector
encoding the hu4D5^8 scFv in a VH-(Gly4Ser)3-VL orientation [27].
Overlapping sequences encoding a non-repetitive linker ([28,10]) were
added at the 5P end of VH and 3P end of VL during the PCR reaction.
The two PCR products were gel puri¢ed and assembled in a further
PCR reaction. The assembled PCR product, encoding the hu4D5^8
scFv in a VL-linker-VH orientation, was cloned into the EcoRV and
EcoRI sites of the secretion vector pIG6 [29], carrying an N-terminal
FLAG and C-terminal Myc- and His-tag sequences. In the case of the
cysteine-free hu4D5 mutant, the primers used for PCR ampli¢cation
of VH and VL encoded point mutations replacing Cys H22 by Val,
Cys H92 by Ala, Cys L23 by Val and Cys L88 by Ala (numbering
according to Kabat [30]).
2.2. Protein expression and puri¢cation
Both the disul¢de-containing 4D5-SS and the cysteine-free 4D5-
SS3 were expressed in the periplasm of E. coli JM83 (V3, ara, v(lac,
proAB), rpsL, thi, x80, dlacZvM15) [31]. Cells were grown in SB
medium at 25‡C and induced in the late logarithmic phase by addition
of 1 mM IPTG. Six hours after induction at 25‡C the cells were
harvested. The cell pellet from 1 l of culture was suspended in 20
ml of 40 mM Tris-HCl pH 7.5, 150 mM NaCl. Cells were lysed using
a French press.
For the 4D5-SS scFv protein, the supernatant of the whole cell
extract was applied to two columns coupled in-line [32]. An immobi-
lized metal ion a⁄nity chromatography (IMAC) column was used
¢rst (making use of the C-terminal His-tag of the scFv fragment)
and the eluate at pH 9.0 was directly pumped onto a HQ-anion ex-
change column from which the 4D5-SS could be eluted with a 0^500
mM NaCl gradient at pH 9.0. The peak fraction was dialyzed against
40 mM Tris pH 9.0, 150 mM NaCl.
The 4D5-SS3 scFv was puri¢ed from the insoluble part of the
whole cell extract. The pellet of the cell extract was suspended in 20
ml 40 mM Tris, pH 8.0, 6 M GdnHCl, and puri¢ed by denaturing
IMAC chromatography. The peak fraction was refolded by 1:100
dilution into a refolding bu¡er (0.5 mM 6-amino-n-caproic acid, 0.8
M arginine, 0.5 mM benzamidine hydrochloride, 2 mM EDTA, 0.2 M
Tris-HCl, pH 9.0). The refolding mixture was incubated at 4‡C for
24^48 h. After concentration of the refolding mixture by a factor of
about 5 using an Amicon model 8200 ultra¢ltration cell, it was dia-
lyzed extensively against 40 mM Tris pH 9.0, 150 mM NaCl to re-
move most of the arginine. The 4D5-SS3 scFv fragment could then be
further puri¢ed by Protein-A Sepharose (Pharmacia-Biotech) chroma-
tography [33]. Bound scFv fragment was eluted in a 100 mM citrate
bu¡er, pH 3.0. The peak fraction was collected in a £ask containing
1 M Tris pH 9.0 to minimize the exposure time of the scFv fragment
to low pH. Bu¡er exchange into 40 mM Tris pH 9.0, 150 mM NaCl
was performed using a PD10 Sephadex G-25M gel ¢ltration column
from Pharmacia-Biotech.
2.3. ELISA measurements
The ELISA plate wells were coated with 50 Wl of 200 nM
p185HER2ÿECD antigen (kindly provided by P. Carter, Genentech
Inc.) in PBS bu¡er, pH 7.0, overnight at 4‡C. Wells were blocked
with 5% milk in PBST for 1 h at room temperature. The respective
scFv fragments (about 300 ng or 10 pmol) were then allowed to bind
in a volume of 100 Wl in PBST bu¡er for 1 h at room temperature.
After two washing steps with water, a 1:2 dilution of an E. coli extract
containing the anti-His-tag-scFv-AP fusion [34] in high TBST, pH 7.0,
was allowed to bind for 1 h at room temperature, and AP activity was
detected as described [34]. Speci¢city of binding was tested by prein-
cubation of scFv (100 nM) with 200 nM soluble p185HER2ÿECD anti-
gen for 10 min at room temperature, before adding the mixture to the
ELISA wells. All measurements were performed in duplicate. An A48
scFv [3], also carrying a C-terminal His-tag, but with di¡erent antigen
speci¢city, was used as a negative control.
2.4. Analytical gel ¢ltration
Analytical gel ¢ltrations were performed with the SMART-system
(Pharmacia), using a Superdex 75 column. All measurements were
carried out in 40 mM Tris-HCl, pH 9.0, 150 mM NaCl with
0.005% Tween-20. The respective scFv fragments were injected at
3 WM in a volume of 50 Wl. The column was calibrated in the same
bu¡er with alcohol-dehydrogenase (150 kDa), bovine serum albumin
(66 kDa), carboanhydrase (29 kDa) and cytochrome c (12.4 kDa) as
molecular mass standards.
2.5. BIAcore measurements
The p185HER2ÿECD antigen at 100 Wg/ml in 20 mM citrate bu¡er,
pH 4.0 was coupled to the sensor chip using an amine coupling
kit (Pharmacia AB Biosensor, Uppsala, Sweden). The two hu4D5
scFv fragments were applied at 2, 5, 10, 15, 20 Wg/ml to the chip at
a £ow rate of 30 Wl/min at 20‡C. The surface was regenerated by
injection of 45 Wl of 0.1 M glycine-HCl, pH 2.2, 0.5 M NaCl. Data
were analyzed using the global ¢t in the BIAevaluation program
version 3.0.
2.6. Urea denaturation measurements
Urea denaturation measurements were performed and analyzed as
described before [10] with the following modi¢cations: ScFv concen-
trations of 5 Wg/ml (about 166 nM) were used, all measurements were
carried out in 40 mM Tris-HCl, pH 9.0, 150 mM NaCl. The dithiol
form of the cysteine-containing 4D5 (4D5-SSred) and the respective
control of the 4D5-SS3 were measured in degassed bu¡er of 20 mM
DTT, 40 mM Tris-HCl pH 7.0, 150 mM NaCl and prepared from
completely denatured and reduced protein. The proteins were incu-
bated for 4 h at room temperature in the latter bu¡er containing 8 M
urea prior to the preparation of the di¡erent samples, to allow com-
plete reduction of the disul¢des in the cysteine-containing 4D5 scFv
fragment. Measurements in the DTT bu¡er were performed at higher
protein concentration (500 nM) to compensate for the absorption
e¡ect of the DTT. Free energies were ¢tted according to Pace [35],
prior to normalization of the denaturation curve to the fraction of
unfolded protein.
FEBS 20229 18-5-98
A. Woºrn, A. Pluºckthun/FEBS Letters 427 (1998) 357^361358
3. Results
3.1. Design of the cysteine replacements
We have replaced the conserved disul¢de bridges in both
the heavy and the light chain of the scFv fragment hu4D5^8
by the amino acid combination Val-Ala. This combination
has been most frequently selected during phage panning
from 25 possible combinations in the case of the disul¢de-
free A48 scFv VL domain [10]. Moreover, Liu et al. [36]
have performed a systematic study on di¡erent replacements
of the disul¢de bridge in bovine pancreatic trypsin inhibitor
and also found the combination Val-Ala to be the least desta-
bilizing one. A Val-Ala pair should have similar steric require-
ments as a disul¢de bridge, and the hydrophobicity of these
two amino acids is compatible with the hydrophobic environ-
ment in the interior of antibody domains. This is important,
because the burial of charges and the creation of unsatis¢ed
hydrogen bonds in a hydrophobic environment, even if steri-
cally possible, would be energetically very unfavorable ([37^
39], among others).
3.2. Protein expression and puri¢cation
The hu4D5 scFv fragment with the conserved disul¢de
bridges in VL and VH accumulated mainly in the soluble frac-
tion, when secreted to the periplasm at 25‡C (Fig. 1). Puri¢-
cation yielded about 10 mg of pure scFv protein per liter E.
coli JM83. In contrast, the same scFv fragment lacking the
two disul¢de bonds could not be puri¢ed from the soluble
fraction after identical expression conditions. Essentially all
4D5-SS3 scFv protein was insoluble in the E. coli periplasm
(Fig. 1). The 4D5-SS3 protein was thus obtained from the
insoluble fraction after IMAC puri¢cation under denaturing
conditions, and the relatively pure IMAC fraction was sub-
jected to in vitro refolding and Protein-A Sepharose chroma-
tography [33] of the dialyzed refolding mixture. Approxi-
mately 1 mg of soluble, refolded cysteine-free scFv could be
obtained from 1 l E. coli.
3.3. ELISA and BIAcore measurements
Both hu4D5 scFv fragments produced a signal in antigen
binding ELISA, which was completely inhibitable by 200 nM
antigen (Fig. 2). The intensities produced by equal amounts of
hu4D5 scFv fragment with or without the disul¢de bridges
were similar. A control scFv (A48) carrying a His-tag, but
directed against a di¡erent antigen (bacterial levan), did not
give rise to any signal, further emphasizing the speci¢city of
the hu4D5 scFv binding to p185HER2ÿECD. The KD values
determined by BIAcore were 121 pM for the 4D5-SS3 scFv
and 194 pM for the 4D5-SS (data not shown).
3.4. Analytical gel ¢ltration
Both the 4D5-SS3 and the 4D5-SS scFv fragment eluted
in a sharp and symmetric peak from the Superdex-75 gel
¢ltration column at an elution volume of 1.21 and 1.20 ml
for 4D5-SS3 and 4D5-SS, respectively. According to the
molecular weight standards, this indicates a MW of about
29 000, and thus monomeric scFv for both molecules.
3.5. Urea denaturation measurements
The denaturation curve of the 4D5-SS scFv had a mid-
point at 4.8 M urea, that of 4D5-SS3 scFv at 3 M urea (Fig.
3). The reduced dithiol form 4D5-SSred of the cysteine-con-
taining 4D5 scFv fragment, measured in 20 mM DTT, had its
urea transition midpoint at 2.8 M urea, while the denaturation
midpoint of the 4D5-SS3 was shown to be not in£uenced by
the presence of DTT, as one would expect from the absence of
any cysteines. All scFv fragments showed a rather steep tran-
sition, suggesting that the unfolding follows a two-state mod-
el. Fitting of the denaturation curves [35] resulted in a stability
of 8.1 kcal/mol for the 4D5-SS (disul¢des intact), about 3.8
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Fig. 2. Antigen binding ELISA of 4D5-SS, 4D5-SS3 and a control
scFv A48. ELISA wells were coated with 50 Wl of 200 nM
p185HER2ÿECD antigen. Binding of 300 ng (about 10 pmol) scFv per
well was performed in the absence (3) or presence (+) of 200 nM
antigen. The 4D5-SS and 4D5-SS3 scFv fragments produced sig-
nals of similar intensities. No signal was produced by a control
scFv fragment with His-tag, but a di¡erent antigen speci¢city (nega-
tive control). Binding could be inhibited with 200 nM p185HER2ÿECD
in all cases, proving the speci¢city of the binding reaction. Binding
was detected with an K-His-tag-scFv-AP [34].
Fig. 1. 12% SDS gel documenting the periplasmic expression and
puri¢cation of hu4D5 scFv with the conserved disul¢de bridges
(4D5-SS) and of the Val-Ala substitution mutant (4D5-SS3) in VH
and VL. Expression was performed at 25‡C. 4D5-SS was mainly in
the supernatant (sup) of the cell extract, 4D5-SS3 was mostly in the
pellet (pel). The peak fraction of 4D5-SS, puri¢ed by IMAC and
HQ-anion exchange chromatography is shown (peak IMAC/HQ).
4D5-SS3 was puri¢ed by denaturing IMAC chromatography (peak
IMAC), refolded in vitro and further puri¢ed by Protein-A Sephar-
ose chromatography (peak Protein A). Note that the pel and peak
IMAC fraction of 4D5-SS3 contain GdnHCl, which disturbs the
band shape.
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kcal/mol for the 4D5-SS3 (Val-Ala protein) with or without
DTT present, and 2.7 kcal/mol for the reduced, dithiol form
4D5-SSred. The Val-Ala replacements in the 4D5-SS3 gave
therefore rise to a slightly more stable protein, compared
with the dithiol form 4D5-SSred of the cysteine-containing
4D5.
4. Discussion
The observed loss of stability between the 4D5-SS and its
dithiol form (about 5.4 kcal/mol) is of the same order of
magnitude as the stability contribution of disul¢de bond in
the CL domain of a type V Bence-Jones protein (4 kcal/mol)
[5], in the CL domain of a type U Bence-Jones protein (4.7
kcal/mol) [40] and in di¡erent mutants of the REIv-U variable
domain (4.5 kcal/mol) [12]. However, one has to take into
account that, in contrast to the examples mentioned above,
two disul¢de bridges are reduced in the scFv fragment 4D5.
Interestingly, the Val-Ala variant of the 4D5 scFv (4D5-SS3)
was found to be slightly more stable (by 1.1 kcal/mol) than
the dithiol form of the cysteine-containing variant (4D5-
SSred). This suggests that by simply replacing the cysteines
by the Val-Ala pair one may already obtain a slight stabilizing
e¡ect for the application as intrabodies, but this may not be
enough by itself.
The hu4D5 scFv fragment, with its urea denaturation mid-
point at 4.8 M, permits an estimate how stable a scFv frag-
ment needs to be in order to allow removal of the disul¢de
bridges without the requirement of introducing further stabi-
lizing mutations. With the midpoint of the denaturation curve
being at 3 M urea, the 4D5-SS3 has a similar thermodynamic
stability as some scFv fragments, which carry the conserved
disul¢de bridges ([41,42]).
An important prerequisite for further studies concerning
disul¢de-free scFv fragments as potential intrabodies is that
the disul¢de-free scFv fragments need to have unchanged
antigen binding properties. X-ray crystallographic studies of
the REIv-U domain suggested that, in the case of this single
domain, removal of the disul¢de bridge did not produce any
obvious local change in the structure [13]. However, no struc-
ture of a VH domain without disul¢de bond has been reported
yet.
For the hu4D5 scFv fragment, we could test the in£uence
of the removed disul¢de bridges directly by functional studies.
The ELISA signals (Fig. 2) showed qualitatively that both the
4D5-SS and the 4D5-SS3 scFv bind speci¢cally to the
p185HER2ÿECD antigen. The antigen dissociation constants de-
termined by BIAcore were also in the same range (121 pM for
the 4D5-SS3, 194 pM for the 4D5-SS). This similarity of
binding clearly shows that the same native structure is reached
in the presence and absence of the disul¢de bonds. These
values are in general agreement with KD values of di¡erent
constructs derived from the hu4D5^8 antibody published pre-
viously (90 pM by RIA for the Fab [22], 290 pM by ELISA
for the F(abP)2 [43]). The binding properties were not in£u-
enced by avidity contributions due to diabody formation [44]
in the present study, because both scFv fragments were shown
to be monomeric by analytical gel ¢ltration.
The observed dramatic di¡erence between the 4D5-SS and
the 4D5-SS3 scFv fragments regarding their solubility in the
E. coli periplasm implies that the conserved disul¢de bridges
in VH and VL are of critical importance for the correct in vivo
folding in the environment of E. coli JM83 periplasm. As
discussed previously [6], this may either be caused by the in-
su⁄cient thermodynamic stability of the 4D5-SS3 variant or
by the fact that early disul¢de formation may be kinetically
required for correct folding in the periplasm. Early disul¢de
formation in the 4D5-SS may prevent certain aggregation
pathways that are accessible to the more extended, disul¢de-
free chain of the 4D5-SS3. We showed previously, however,
that the disul¢de-free version of the scFv A48 can be func-
tionally obtained from the cytoplasm [10]. The quantitative
folding of the variants in the cytoplasm of di¡erent cells,
which may provide di¡erent sets of molecular chaperones to
disallow these aggregation pathways, still needs to be com-
pared.
ScFv fragments expressed in the reducing environment of
the cytoplasm in eukaryotic cells were shown to have reduced
cysteine thiol groups [18], and the disul¢de bridge indeed does
not seem to be formed in the cytoplasm. Expression of ‘nor-
mal’ scFv fragments and derivatives, like the 4D5-SS3 re-
ported here, with replaced cysteine residues may lead to an
answer of the question whether, under in vivo conditions, the
Val-Ala combination as a replacement for the disul¢de bridge
is indeed superior to two reduced cysteine thiol groups in the
interior of the antibody variable domain, provided su⁄ciently
stable scFv fragments are compared.
The most important conclusion from this and previous
studies for intrabody applications is, however, that a mini-
mum stability is necessary for the scFv fragment to fold under
reducing conditions, or to tolerate the removal of the disul¢de
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Fig. 3. Urea denaturation transitions of 4D5 scFv fragments with
(4D5-SS) and without (4D5-SS3) cysteines. The scFv 4D5-SS,
carrying the conserved disul¢de bridges, is shown in open circles
(a). The corresponding dithiol form 4D5-SSred is shown in ¢lled
circles (b). The scFv 4D5-SS3, lacking all cysteines and thus the di-
sul¢des, is shown in the presence (R) and in the absence (O) of
DTT. The presence of DTT did not signi¢cantly a¡ect the stability
of the 4D5-SS3, which contains no cysteines. In contrast, the re-
duced dithiol form 4D5-SSred (b) of the cysteine-containing variant
is signi¢cantly less stable than the oxidized form 4D5-SS (a) and
even less stable than the Val-Ala mutant (R, O). Equilibrium un-
folding in the absence of DTT (open symbols) was induced by incu-
bating scFv solutions with increasing concentrations of urea. Meas-
urements in the presence of DTT (¢lled symbols) were started from
protein, which had been completely denatured and reduced with 20
mM DTT, pH 7.0, in 8 M urea for 4 h at room temperature. Dena-
turation transitions were measured by the shift in £uorescence emis-
sion maximum with changing urea concentration and are normal-
ized to fraction unfolded (FU) protein.
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bond by Val-Ala pairs. We suggest that only few natural anti-
body fragments will have the required stability without further
engineering. Thus, three approaches can be envisaged to ar-
rive at a scFv fragment which does not require disul¢de
bonds. First, a given antibody can be stabilized by evolution-
ary approaches as previously shown in the case of the scFv
ABPC48 [10]. Second, a very stable framework such as hu4D5
can be used as recipient for the CDRs of interest [45]. Third, a
CDR library on such a framework as the one described here
can be constructed to select directly the disul¢de-free variants.
In all three approaches, the use of Val-Ala replacement for the
cysteines seems advantageous, because of its slightly increased
stability, compared with the dithiol form of cysteine-contain-
ing scFv fragments. A rigorous, quantitative approach will be
necessary to further develop the technology of intrabodies.
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